Publications

5674 Results

Fludarabine and cyclophosphamide produces a higher complete response rate and more durable remissions than fludarabine in patients with previously untreated CLL: Intergroup trial E2997

Authors
IW Flinn;E Kumm;MR Grever;D Neuberg;GW Dewald;JM Bennett;EM Paietta;FR Appelbaum;RA Larson;MA Hussein;DF Moore Jr;MS Tallman
Journal / Conference
Blood 104(11): #475
Year
2004
Research Committee(s)
Leukemia
Study Number(s)
E2997

Enhancing well-being during breast cancer recurrence: preliminary findings from a phase III study

Authors
CC Gotay;CM Moinpour;CS Jiang;DP Ankerst;D Coleman;S Martino;B Taylor;J Bearden;S Dakhil;H Gross;DS Albain
Journal / Conference
Breast Cancer Research and Treatment 88(Suppl 1):S140 (#3080)
Year
2004
Research Committee(s)
Breast
Study Number(s)
S9632, S9832

Under-representation of elderly patients in cancer clinical trials: causes and remedial strategies

Authors
JM Unger;LF Hutchins;KS Albain
Journal / Conference
Comprehensive Geriatric Oncology 2nd ed. Taylor & Francis; 2004, Chapter 22
Year
2004

The prostate cancer prevention trial: the association of study site and participant adherence interventions to the study site end-of-study biopsy rates

Authors
S Carlin;P Goodman;C Moinpour;C Tangen
Journal / Conference
Clinical Trials 1 (Suppl 1):P45
Year
2004
Research Committee(s)
Cancer Control
Study Number(s)
SWOG-9217

Extreme regression: a statistical technique for finding good or poor prognostic groups, illustrated using myeloma patient data from Intergroup trial S9321

Authors
JJ Crowley;J McCoy;M LeBlanc;B Barlogie
Journal / Conference
Blood 104(11): #5202
Year
2004
Research Committee(s)
Myeloma
Study Number(s)
SWOG-9321

Clinical, laboratory, and treatment outcome characteristics of chronic lymphocytic leukemia (CLL) patients with p53 mutations or del(17p) enrolled on a prospective phase III clinical trial: short progression free survival, irrespective of fludarabine-based treatment used

Authors
DM Lucas;GW Dewald;DS Neuberg;JC Byrd;G Lozanski;J Harbison;KD Cunningham;IW Flinn;MS Tallman;MR Grever
Journal / Conference
Blood 104(11): #949
Year
2004
Research Committee(s)
Leukemia
Study Number(s)
E2997

Critical molecular studies to strategically plan therapy in chronic lymphocytic leukemia (CLL): correlating cellular proteins with defined prognostic patient subsets and their response to treatment

Authors
S Kitada;JC Reed;DM Lucas;DS Neuberg;JG Gribben;GW Dewald;IW Flinn;MS Tallman;JC Byrd;MR Grever
Journal / Conference
Blood 104(11):956
Year
2004
Research Committee(s)
Leukemia
Study Number(s)
E2997

Outcome of treatment with fludarabine versus fludarabine and cyclophosphamide in chronic lymphocytic leukemia (CLL) is adversely impacted by high risk genetic features: results from ECOG 2997

Authors
MR Grever;DM Lucas;GW Dewald;DS Neuberg;IW Flinn;MS Tallman;JG Gribben;JC Byrd
Journal / Conference
Blood 104(11):#3487
Year
2004
Research Committee(s)
Leukemia
Study Number(s)
E2997

BCL2 translocation defines a unique tumor subset within the germinal center B-cell-llike diffuse large B-cell lymphoma

Authors
J Iqbal;WG Sanger;DE Horsman;A Rosenwald;DL Pickering;B Dave;L Xiao;K Cao;Q Zhu;S Sherman;CP Hans;CC Weisenburger;TC Greiner;RD Gascoyne;G Ott;HK Muller-Hermelink;J Delabie;RM Braziel;ES Jaffe;E Campo;JC Lynch;JC Lynch;JM Connors;JM Vose;JO Armitage;TM Grogan;LM Staudt;WC Chan
Journal / Conference
American Journal of Pathology 165(1):159-166
Year
2004
Research Committee(s)
Lymphoma
Study Number(s)
SWOG-8819

When will melanoma vaccines be proven effective?

Authors
JA Sosman;AT Weeraratna;VK Sondak
Journal / Conference
Journal of Clinical Oncology 22(3):387-389
Year
2004
Research Committee(s)
Melanoma